Global B2B Pharmaceutical Marketplace · Sourcing · Named-Patient Access
💬 WhatsApp · Sign in · Register
Secukinumab bulk supplier for pharma manufacturers

Secukinumab 150 mg/mL Suppliers & Bulk Manufacturers

Available Forms: Injection

Available Strengths: 150 mg/mL

Reference Brands: Cosentyx

Category: Osteoporosis

Cosentyx (Secukinumab) 150 mg/mL is approved for psoriasis and arthritis. Available as autoinjector and syringe. Ideal for global pharma B2B supply.

Get Enquiry / Request Bulk Quote

Quick Response Guaranteed | Verified Suppliers

📘 Sourcing Guide

Product Description:

Secukinumab (Cosentyx®) is a leading IL-17A monoclonal antibody approved for the treatment of moderate-to-severe plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It is available as a 150 mg/mL prefilled syringe or autoinjector, designed for convenient subcutaneous administration. Trusted globally under the Cosentyx brand by Novartis, it is used in dermatology and rheumatology settings across the US and EU. Manufactured under GMP/ICH-compliant standards, Secukinumab is ideal for B2B pharmaceutical buyers, including hospitals, clinics, and specialty pharmacies. Contact us for bulk export, regulatory support, and competitive pricing.

Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'

The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing

Frequently Asked Questions

Secukinumab is used to treat autoimmune diseases such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. It works by inhibiting interleukin-17A (IL-17A), a cytokine involved in inflammatory and immune responses.

Secukinumab is a fully human monoclonal antibody produced using recombinant DNA technology in Chinese hamster ovary (CHO) cells. It specifically targets and binds to interleukin-17A, blocking its interaction with the IL-17 receptor.

The trade name of Secukinumab is Cosentyx.

Secukinumab is developed and manufactured by Novartis Pharmaceuticals.

The generic name is Secukinumab.

The brand name is Cosentyx.

Secukinumab is primarily manufactured by Novartis in Switzerland and other global manufacturing facilities that follow international GMP standards.

Related Products

Strontium Ranelate

Strength:
2 g

Form: Sachet

Reference Brands: Osseor (EU/UK)

View Details
Abaloparatide

Strength:
80 mcg

Form: injection (prefilled syringe)

Reference Brands: Tymlos (USA), Eladynos (EU)

View Details
Pamidronate Disodium

Strength:
15 mg, 30 mg, 60 mg, 90 mg

Form: Injection

Reference Brands: Aredia (USA/EU)

View Details
Calcitonin Salmon

Strength:
100 IU/mL, 200 IU/mL

Form: Injection / nasal spray

Reference Brands: Fortical (USA), Miacalcin (USA)

View Details
Enquire Now

Quick Response Guaranteed | Verified Suppliers

Subscribe to Our Newsletter

Stay updated on pharma trends and marketplace opportunities.

Please enter the correct answer.
This website uses cookies to ensure you get the best experience. By using our site, you agree to our Privacy Policy.